Entropy Advances TRP-8803 to US Phase 2 in Depression
Filed with ASX · · 6 pages · English
Entropy Neurodynamics Limited on 6ix
In the deck
Earlier from Entropy Neurodynamics
- TRP 8803 manufacturing secured for Phase 2/3 advancement
- 72 patient multi-indication trial approved to fast track TRP-8803 commercialisation
- 72-Patient Trial Fast-Tracks TRP-8803 Commercialisation
- South Africa Grants ENP Broad Fibromyalgia Patent to 2043
- 100% Clinical improvement, 50% Remission in BED study
Later from Entropy Neurodynamics
- Appendix 4E and 2026 Annual Report
- All Patients Improve, 50% Achieve 12-Week BED Remission
- TRP-8803 60-Minute Infusion Achieved in Phase 2 BED Study
- Quarterly Activities Report and Appendix 4C
Follow Entropy Neurodynamics into a list and get an email when it puts out news.
Follow Entropy Neurodynamics